1. Home
  2. DUO vs ENVB Comparison

DUO vs ENVB Comparison

Compare DUO & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DUO

Fangdd Network Group Ltd.

HOLD

Current Price

$1.12

Market Cap

7.5M

Sector

Finance

ML Signal

HOLD

Logo Enveric Biosciences Inc.

ENVB

Enveric Biosciences Inc.

HOLD

Current Price

$2.28

Market Cap

8.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DUO
ENVB
Founded
2011
1994
Country
China
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
8.1M
IPO Year
2018
2000

Fundamental Metrics

Financial Performance
Metric
DUO
ENVB
Price
$1.12
$2.28
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
55.7K
368.0K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$39,914,675.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$0.56
52 Week High
$5.34
$13.25

Technical Indicators

Market Signals
Indicator
DUO
ENVB
Relative Strength Index (RSI) 37.13 41.84
Support Level $1.02 $1.83
Resistance Level $1.25 $4.29
Average True Range (ATR) 0.10 0.21
MACD -0.04 -0.05
Stochastic Oscillator 25.39 38.05

Price Performance

Historical Comparison
DUO
ENVB

About DUO Fangdd Network Group Ltd.

Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.

About ENVB Enveric Biosciences Inc.

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

Share on Social Networks: